相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pharmacogenetics of Pregnancy-Induced Changes in Efavirenz Pharmacokinetics
A. Olagunju et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Does pregnancy affect the pharmacokinetics of efavirenz?
Andrew Hill et al.
AIDS (2014)
Treatment Optimization in Patients Co-Infected with HIV and Mycobacterium tuberculosis Infections: Focus on Drug-Drug Interactions with Rifamycins
Mario Regazzi et al.
CLINICAL PHARMACOKINETICS (2014)
Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial
Rebekah L. Puls et al.
LANCET (2014)
Pharmacogenetic-Based Efavirenz Dose Modification: Suggestions for an African Population and the Different CYP2B6 Genotypes
Jackson K. Mukonzo et al.
PLOS ONE (2014)
CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults
Adeniyi Olagunju et al.
PHARMACOGENETICS AND GENOMICS (2014)
CYP2B6 516G>T (rs3745274) and Smoking Status Are Associated With Efavirenz Plasma Concentration in a Serbian Cohort of HIV Patients
Adeniyi Olagunju et al.
THERAPEUTIC DRUG MONITORING (2014)
Relationship Between Weight, Efavirenz Exposure, and Virologic Suppression in HIV-Infected Patients on Rifampin-Based Tuberculosis Treatment in the AIDS Clinical Trials Group A5221 STRIDE Study
Anne F. Luetkemeyer et al.
CLINICAL INFECTIOUS DISEASES (2013)
Neuronal toxicity of efavirenz: a systematic review
Eric H. Decloedt et al.
EXPERT OPINION ON DRUG SAFETY (2013)
Would a CYP2B6 test help HIV patients being treated with efavirenz?
Chonlaphat Sukasem et al.
PHARMACOGENOMICS (2013)
Correlates of Efavirenz Exposure in Chilean Patients Affected With Human Immunodeficiency Virus Reveals a Novel Association With a Polymorphism in the Constitutive Androstane Receptor
Claudia P. Cortes et al.
THERAPEUTIC DRUG MONITORING (2013)
PXR and CAR single nucleotide polymorphisms influence plasma efavirenz levels in South African HIV/AIDS patients
Marelize Swart et al.
BMC MEDICAL GENETICS (2012)
Pharmacokinetic and Pharmacodynamic Analysis of Efavirenz Dose Reduction Using an In Vitro-In Vivo Extrapolation Model
M. Siccardi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants
Emily R. Holzinger et al.
PHARMACOGENETICS AND GENOMICS (2012)
Dendritic Spine Injury Induced by the 8-Hydroxy Metabolite of Efavirenz
Luis B. Tovar-y-Romo et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens
Christoph Wyen et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Association of Pharmacogenetic Markers with Premature Discontinuation of First-line Anti-HIV Therapy: An Observational Cohort Study
Rubin Lubomirov et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
A Systematic Review of the Psychiatric Side-Effects of Efavirenz
Christopher A. Kenedi et al.
AIDS AND BEHAVIOR (2011)
CYP2B6 (c.516G→T) and CYP2A6 (*9B and/or*17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients
Awewura Kwara et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans
Jackson K. Mukonzo et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Pharmacogenetics-Based Population Pharmacokinetic Analysis of Efavirenz in HIV-1-Infected Individuals
M. Arab-Alameddine et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function
Julia di Iulio et al.
PHARMACOGENETICS AND GENOMICS (2009)
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients
Christoph Wyen et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
High prevalence of the CYP2B6 516G→T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe
Christopher Nyakutira et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P4502B6*6 and*26
Hiroyuki Gatanaga et al.
CLINICAL INFECTIOUS DISEASES (2007)
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV
JE Gallant et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring
F Gutiérrez et al.
CLINICAL INFECTIOUS DISEASES (2005)
Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals
DB Clifford et al.
ANNALS OF INTERNAL MEDICINE (2005)
Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals
BS Kappelhoff et al.
CLINICAL PHARMACOKINETICS (2005)
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
C Marzolini et al.
AIDS (2001)
分享论文
